COMPASS Pathways (CMPS)
(Real Time Quote from BATS)
$7.31 USD
+0.37 (5.33%)
Updated Jul 25, 2024 12:34 PM ET
3-Hold of 5 3
D Value C Growth A Momentum C VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
CMPS 7.31 +0.37(5.33%)
Will CMPS be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for CMPS based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for CMPS
COMPASS Pathways PLC Sponsored ADR (CMPS) Just Flashed Golden Cross Signal: Do You Buy?
Pediatrix (MD) Down 4.2% Despite Q1 Earnings & Revenue Beat
CMPS: What are Zacks experts saying now?
Zacks Private Portfolio Services
Is Cardinal Health (CAH) Stock Outpacing Its Medical Peers This Year?
All You Need to Know About COMPASS Pathways PLC Sponsored ADR (CMPS) Rating Upgrade to Strong Buy
Are Medical Stocks Lagging COMPASS Pathways (CMPS) This Year?
Other News for CMPS
Compass a new outperform at RBC on optimism for psychedelic-based therapies
Compass Pathways initiated with bullish view at RBC Capital, here's why
Here's What You Missed in Cannabis, Psychedelics This Week
Here's What You Missed in Cannabis, Psychedelics This Week
Compass Pathways appoints Lori Englebert as Chief Commercial Officer